Table 2.
Patient characteristics in the pooled clinical trials sample
| FSC group (N = 776) | SAL group (N = 778) | |
|---|---|---|
| Clinical trial SCO40043 | 391 (50.4) | 385 (49.5) |
| Clinical trial SCO100250 | 385 (49.6) | 393 (50.5) |
| Age, mean (SD) | 65.1 (9.1) | 65.1 (9.0) |
| Male, mean (SD) | 424 (54.6) | 424 (54.5) |
| Race, N (%) | ||
| Black | 33 (4.3) | 40 (5.1) |
| Caucasian | 728 (93.8) | 729 (93.7) |
| Other | 15 (1.9) | 9 (1.2) |
| Body mass index, mean (SD) | 27.5 (6.2) | 27.4 (7.0) |
| Smoking status, N (%) | ||
| Current smoker | 320 (41.3)a | 317 (40.7) |
| Former smoker | 455 (58.7)a | 461 (59.3) |
| Pack-years, mean (SD) | 58.1 (31.8) | 55.3 (26.7) |
| COPD duration, mean (SD) | 8.2 (7.6) | 8.1 (7.4) |
| COPD type, N (%) | ||
| Chronic bronchitis | 219 (28.2) | 242 (31.1) |
| Emphysema | 360 (46.4) | 333 (42.9)a |
| Both | 197 (25.4) | 202 (26.0) |
| FEV1% predicted, mean (SD) | 33.4 (10.8) | 33.3 (10.3) |
| FEV1/FVC, mean (SD) | 0.45 (0.1) | 0.45 (0.1) |
| Region, N (%) | ||
| Canada | 93 (12.0) | 94 (12.1) |
| Mid-Atlantic | 147 (18.9) | 136 (17.5) |
| Midwest | 96 (12.4) | 91 (11.7) |
| North | 82 (10.6) | 80 (10.3) |
| Northeast | 96 (12.4) | 93 (12.0) |
| South | 69 (8.9) | 78 (10.0) |
| Southeast | 98 (12.6) | 101 (13.0) |
| West | 95 (12.2) | 105 (13.5) |
Notes:
a
Data missing for one patient; denominator is one less than total sample N
Abbreviations: FSC, fluticasone propionate/salmeterol 250 μg/50 μg; SAL, salmeterol 50 μg; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume; FVC, forced vital capacity.